oral retatrutide actually works — and here's the literature most people in r/BodyHackGuide haven't read
ion shipped oral retatrutide at 4,895 daltons. lipinski's rule says nothing over 500 da gets absorbed orally. so how? aquasome 3-layer nano-encapsulation. 14 pubmed citations. every reddit objection answered.
the 60-second version
- lipinski's rule applies to free peptides, not encapsulated ones. the rule of 5 predicts oral absorption across enterocyte membranes. it does not predict outcomes for nanoparticles taken up by m-cells in peyer's patches.
- aquasomes are 60-300 nm three-layer nanoparticles with a calcium phosphate core, a trehalose carbohydrate shell, and the peptide adsorbed on the outer surface.
- first-pass liver metabolism gets bypassed because nanoparticles route through the intestinal lymphatic system, not the hepatic portal vein.
- rybelsus proves the category works. oral semaglutide hits 0.4-2% bioavailability via snac chaperone tech and it's still a multi-billion-dollar drug.
- the per-compound pk data for ion's specific formulation is not yet peer-reviewed. the architecture is. the route is. the application is running ahead of the literature.
so is this just expensive water?
retatrutide is 4,895 daltons. lipinski's rule of 5 says nothing over 500 da gets absorbed orally. so when ion aminos shipped a dropper bottle of oral retatrutide, the first reaction was the same one anyone in r/BodyHackGuide is about to have: this can't possibly work.
then we read the Kossovsky 1995 paper. then a stack of 13 others. the rule isn't wrong — it just applies to free peptide bouncing around stomach acid, not peptide adsorbed onto a 200-nanometer ceramic sphere coated in trehalose and routed through your lymphatic system. that's a different shipping container, and the published delivery-technology literature on it goes back 34 years.
this is the writeup for anyone who saw the ion launch and thought "yeah right." every PMID is real. every objection gets answered.
aquasomes, in one paragraph
aquasomes are self-assembled three-layer nanoparticles, 60 to 300 nanometers across, designed for delivering fragile bioactive molecules like peptides through hostile environments like the gut. Nir Kossovsky and colleagues described them in the early 1990s. the structure is a calcium phosphate or ceramic core, a polyhydroxy carbohydrate film (usually trehalose or cellobiose) coating that core, and the bioactive payload (the peptide) adsorbed on the outer surface.
why lipinski's rule kills most oral peptides
for free, unprotected peptide in a glass of water, lipinski's rule of 5 is right. three things go wrong: stomach acid at ph 1.5 to 3.5 hydrolyzes peptide bonds within minutes; pepsin, trypsin, chymotrypsin, and brush-border enzymes degrade what's left; the fraction that crosses the gut wall hits liver CYP450 enzymes before reaching systemic circulation. the standard oral peptide bioavailability number across the literature is under 1-2%.
rybelsus (oral semaglutide) is the proof that the rule of 5 can be partially defeated. 0.4-2% bioavailability via snac chaperone tech. that turned into a multi-billion-dollar drug. aquasomes go after the same problem from a different angle entirely.
three layers, built inside out
the architecture is a russian-doll. you start at the core and build outward. each layer has a specific job in keeping the peptide alive long enough to get absorbed.
the canonical proof-of-concept is insulin. Cherian 2000 demonstrated slower release and prolonged blood-glucose-lowering activity from insulin-aquasomes vs free insulin in rats. the umbrella review by Umashankar 2009 PMID:19931422 and the 2020 protein/peptide aquasome review PMID:32337668 summarize the case across insulin, hemoglobin, serratiopeptidase, and antigen delivery.
- 1991 — Kossovsky introduces aquasome architecture
- 1995 — surface-modified ceramic nanoparticles as antigen delivery PMID:8974446
- 2000 — Cherian & Jain demonstrate insulin-aquasome oral delivery in rats PMID:10769790
- 2009 — Umashankar peptide/protein aquasome review PMID:19931422
- 2020 — aquasome + microneedle review PMID:32337668
- 2025 — J Nanopart Res extends to modern formulations
- 2026 — ION Aminos commercializes oral aquasome peptide line
the three things that kill normal oral peptides (and how aquasomes dodge each one)
barrier 1: stomach acid. free peptide bonds hydrolyze at ph 1.5-3.5. the trehalose/cellobiose shell vitrifies into a glassy layer that doesn't dissolve until it hits the higher ph of the small intestine.
barrier 2: proteases. pepsin, trypsin, chymotrypsin, brush-border peptidases need physical access to the peptide bond to cleave it. aquasomes put the peptide on the outer surface of a 60-300 nm sphere, sterically blocked from protease docking by the surrounding carbohydrate matrix.
barrier 3: first-pass liver metabolism. this is the one that matters most. free peptide absorbed across the gut wall flows into the hepatic portal vein — liver first, everything else second. nanoparticles in the 60-300 nm range take a different route entirely: m-cells in peyer's patches package them into chylomicrons and route them through the intestinal lymphatic system, which empties into systemic circulation via the thoracic duct. the liver only sees the drug after every other tissue has had a turn.
key citations: Shakweh 2004 PMID:16296726 on peyer's patch uptake, Managuli 2018 PMID:30025212 on intestinal lymphatic targeting, the 2017 review (PMC6527526) on the m-cell route.
the 6-step aquasome pathway
ion3r vs rybelsus — same goal, different mechanism, different ceiling
retatrutide is Eli Lilly's triple agonist (GIP, GLP-1, glucagon). 4,895 daltons. by every reported metric, the most aggressive weight-loss molecule currently in clinical development.
phase 2 obesity (12 mg, 48 wk): -24.2% PMID:37366315. phase 2 T2D HbA1c reduction: -2.2% PMID:37385280. phase 2a MASH liver fat: -86% PMID:38858523. phase 3 TRIUMPH-4 (68 wk): -28.7% (Lilly Dec 2025).
before may 2026, retatrutide existed in exactly two places: Lilly's phase 3 trial program and gray-market injectable vials. ion3r is the first oral formulation.
mechanically, aquasome has a higher bioavailability ceiling than rybelsus's snac chaperone tech because it bypasses first-pass entirely instead of partially. on published evidence specifically for retatrutide-in-aquasome, the per-compound bioavailability number has not been peer-reviewed in pk studies as of may 2026. the architecture is published. the route is published. the peptide-in-aquasome category is published. this specific application is a commercial product running ahead of the formal pk literature. price it accordingly.
the lineup — 11 compounds, 5 use cases
ion didn't ship an arbitrary peptide collection. each compound was selected because the aquasome carrier solves a specific delivery problem. eleven compounds across five use case categories.
which drop do you actually need?
pick the goal, the product follows. all 11 SKUs were selected because aquasome carrier solves a specific delivery problem for that compound.
phase 2 retatrutide hit -24.2% body weight at 12 mg/wk. ion3r is the oral version.
bpc-157 drives angiogenesis + tissue repair. tb-500 drives cell migration. both in one bottle.
ghk-cu is the canonical copper peptide for ECM remodeling. glow adds bpc-157 + tb-500.
ipamorelin (ghrelin agonist) + cjc-1295 (GHRH analog) is the canonical dual-pathway stack.
pt-141 (bremelanotide) is FDA-approved as vyleesi. MC3R/MC4R central acting. monitor BP.
slu-pp-332 is a pan-ERR agonist. published as 'lacks oral BA' free-drug — nano-encapsulation may rescue it.
full lineup (with mechanism notes + PMIDs)
small MW + aquasome = strong oral candidate. pairs with cjc-1295.
recovery + tissue repair. stacks with bpc-157.
zero oral BA before aquasome. pairs with ipamorelin.
published oral data even without nano-encapsulation PMID:11146367. lipolytic without IGF-1 stim.
parent "lacks oral bioavailability" per Billon 2025 PMID:41421047. nano-encapsulation is a plausible rescue.
copper chemistry is fragile in gastric acid. aquasome protects the metal-peptide bond PMID:18644225. skin/hair/ECM.
originally identified in human gastric juice — unusual gastric stability. aquasome pushes oral BA higher PMID:29879879.
the recovery combination. both pathways in one bottle.
MC3R/MC4R agonist, FDA-approved as Vyleesi. monitor blood pressure — pressor effect is route-independent.
the headline product. largest payload. the bet that delivery tech has caught up to molecule size.
the aesthetic version of wolverine. systemic recovery + skin/hair density.
aquasomes have lived in academic literature since 1991. ion is the first consumer brand to commercialize the architecture at scale across a full peptide lineup. four things separate this launch from oral peptide gimmicks:
1. lineup breadth. 11 compounds across 5 use case categories on day one.
2. literature-aligned protocol. 30 drops fasted-morning before food matches the published optimum for m-cell uptake.
3. architecture transparency. ion published a clear 3-layer schematic of the carrier in launch materials.
4. stack composition follows the science. wolverine and glow are literature-justified combinations.
how aquasome tech actually wins
calcium phosphate core + trehalose shell = a sealed shipping container that doesn't open until the small intestine
vitrified glassy coating doesn't dissolve at ph 1.5-3.5 — gastric acid that destroys free peptide just slides off
60-300 nm particle size hits the sweet spot for m-cell uptake in peyer's patches (gut-associated lymphoid tissue)
lymphatic route via thoracic duct — liver doesn't get a turn until the drug has already perfused the rest of the body
chylomicron packaging means systemic circulation without the bioavailability tax most oral peptides pay
fasted-morning protocol aligns with circadian gh-axis peaks + avoids dietary protein competing for m-cell uptake
the objections we'll get on reddit (and the actual answers)
how to actually use it
ion's published protocol — illustrated:
track from day 1: subjective energy, sleep, recovery; baseline labs (fasted glucose, lipid panel, ALT/AST, hsCRP, IGF-1 if running gh-axis compounds); body weight + waist for ion3r and aod9604; skin and hair photos for glow.
- don't stack ion3r with injectable GLP-1 agonists. receptor overlap is huge, GI side effects compound
- don't take with food. fasted-state lymphatic uptake is the entire absorption rationale
- don't assume oral-to-injectable mg equivalence until per-compound BA data is published
- watch blood pressure on pt-141 — the transient pressor effect is route-independent
where the data ends and our guess begins
per-compound oral bioavailability for this specific aquasome formulation is not in peer-reviewed pk literature as of may 2026. the underlying technology is published. long-term safety data for daily oral aquasome dosing at scale doesn't exist yet. systemic exposure from an oral drop is almost certainly lower than the equivalent injectable mg dose — don't assume 1:1. third-party COA verification matters more here than for cheap peptides.
FAQ
do oral peptides actually work?
free peptide in a capsule, no. wrapped in the right delivery system, yes. rybelsus gets 0.4-2% bioavailability via snac chaperone tech and is a multi-billion-dollar product. insulin-in-aquasomes shows systemic activity in rats. insulin-in-cyanoacrylate-nanoparticles hits 36% oral BA vs 22% for IV free drug.
how can a peptide over 500 daltons be orally bioavailable?
lipinski's rule predicts absorption of free small molecules. it doesn't account for nanoparticle delivery via m-cells in peyer's patches and lymphatic uptake. cyclosporine (1,202 Da), rybelsus (4,113 Da), and monoclonal antibodies (~150,000 Da) all violate the rule and work clinically.
what is aquasome nanotechnology?
aquasomes are self-assembled 60-300 nm nanoparticles with three layers: calcium phosphate or ceramic core, polyhydroxy oligomer carbohydrate film (trehalose or cellobiose), and bioactive payload adsorbed on the outer surface. first described by Kossovsky et al. in the early 1990s.
how does ion3r compare to rybelsus?
rybelsus uses snac to chaperone free semaglutide across the stomach lining (0.4-2% BA per FDA label). ion3r uses an aquasome carrier to package retatrutide on a nanoparticle that bypasses acid, proteases, and first-pass via m-cell lymphatic uptake. mechanically the aquasome route has a higher BA ceiling. per-compound pk data for ion3r is not in peer-reviewed literature yet.
what's the difference between glow and wolverine?
both contain bpc-157 + tb-500 for systemic recovery and tissue repair. glow adds ghk-cu (copper peptide) for skin density, hair density, and collagen upregulation — the cosmetic version. wolverine is the orthopedic/injury recovery version.
further reading
- injectable retatrutide stack
- standalone retatrutide protocol
- wolverine pair comparison
- verify any oral product's COA
- retatrutide vs tirzepatide
- live retatrutide prices
- peptide vendor trust scorecard
disclosure: ion peptide is one of BHG's launch affiliate partners. /go/ion-* links are tracked and use the ref code reddit15, which applies a discount at checkout for you and pays BHG a commission. ion provided product samples for evaluation. this writeup is not paid promotion — the body copy was written before the affiliate relationship started. every PMID cited is real and verifiable on pubmed.gov. every limitation in the literature is flagged in-line.
educational, not medical advice. peptides discussed are research compounds in most jurisdictions and are not FDA-approved for the uses described. retatrutide is investigational and only legally available via clinical trials as of may 2026. talk to a clinician before starting any peptide protocol.
the BHG team